Madopar 125/Madopar 250/Madopar Dispersible 125/Madopar HBS 125

Madopar 125/Madopar 250/Madopar Dispersible 125/Madopar HBS 125 Use In Pregnancy & Lactation

benserazide + levodopa

Manufacturer:

Roche

Marketer:

DKSH
Full Prescribing Info
Use In Pregnancy & Lactation
Females and Males of Reproductive Potential: Fertility: No fertility studies have been performed (see Pharmacology: Toxicology: Nonclinical Safety under Actions).
Pregnancy testing: A pregnancy test prior to treatment is recommended to exclude pregnancy.
Contraception: Adequate contraception should be used in women of childbearing potential during treatment with Madopar.
Pregnancy:
Madopar is contraindicated during pregnancy and in women of childbearing potential in the absence of adequate contraception (see Contraindications and Pharmacology: Toxicology: Nonclinical Safety: Reproductive Toxicity and Other under Actions).
If pregnancy occurs in a woman taking Madopar, the drug must be discontinued (as advised by the prescribing physician).
Labor and Delivery: The safe use of Madopar during labor and delivery has not been established.
Lactation: The safe use of Madopar during lactation has not been established.
It is not known whether benserazide is excreted in human breast milk. Mothers requiring Madopar treatment should not nurse their infants, as the occurrence of skeletal malformations in the infants cannot be excluded.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in